<DOC>
	<DOC>NCT00224146</DOC>
	<brief_summary>This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)</brief_summary>
	<brief_title>Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency Patients for whom Oxytrol(r) is contraindicated. Patients treated with Oxytrol(r) prior to participation in this study. Patients residing in longterm care facilities or nursing homes.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Oxytrol(r)</keyword>
	<keyword>transdermal oxybutynin</keyword>
	<keyword>overactive bladder</keyword>
</DOC>